Home > Insider Trading > Filing (0001209191-17-033593)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1481512	Ra Pharmaceuticals Inc.	RARX	Pharmaceutical Preparations (2834)	V8

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1114448	Ag Novartis	Lichtstrasse 35 Basel V8 4056		No	No	Yes	No
1297709	Ltd Bioventures Novartis	C/O Novartis International Ag Wsj-200.220 Basel V8 CH-4002		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2017-05-16	20,081	$26.33	2,440,956	No	4	S	Direct
Common Stock	Disposition	2017-05-17	22,534	$25.51	2,418,422	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Footnotes

Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $25.45 to $26.73 on May 16, 2017 and $25.00 to $26.73 on May 17, 2017. The prices reported reflect the weighted average sale prices. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
The board of directors of Novartis Bioventures Ltd. has sole voting and investment control and power over such securities. None of the members of its board of directors has individual voting or investment power with respect to such securities and each disclaims beneficial ownership of such securities. Novartis Bioventures Ltd. is an indirectly owned subsidiary of Novartis AG.